Literature DB >> 32674108

Triphala Ameliorates Nephropathy via Inhibition of TGF-β1 and Oxidative Stress in Diabetic Rats.

Sachin V Suryavanshi1, Mayuresh S Garud1, Kalyani Barve1, Veeranjaneyulu Addepalli1, Sachin V Utpat2, Yogesh A Kulkarni3.   

Abstract

INTRODUCTION: Advanced glycation end products, oxidative stress, and TGF-β expression play a crucial role in pathophysiology of diabetic nephropathy. Inhibition of oxidative stress and TGF-β expression by natural traditional medicines may give an economic and safe alternative treatment option. Triphala churna, a traditional medicine, has been proved to have potent antioxidant activity, and individual components of it have shown significant antidiabetic activity. Hence, the present study was designed to study the effect of Triphala churna in diabetic nephropathy in rats.
METHODS: Diabetes was induced in rats by administration of streptozotocin (55 mg/kg i.p.). Four weeks after induction of diabetes, the animals were treated with Triphala churna at the doses of 250, 500, and 1,000 mg/kg for next 4 weeks. Various biochemical and urine parameters such as glucose, creatinine, blood urea nitrogen (BUN), total protein, and albumin were assessed at the end of study. Creatinine clearance, BUN clearance, and glomerular filtration rate were determined. Oxidative stress parameters such as malondialdehyde, catalase, reduced glutathione, and superoxide dismutase were determined in kidney tissues. TGF-β1 expression was measured with ELISA, immunohistochemistry, and western blot techniques. Histopathology study was carried out with haemotoxylin and eosin, periodic acid-Schiff, and Masson's trichrome staining to determine histological changes.
RESULTS: Treatment with Triphala churna significantly improved urine parameters. Triphala churna treatment also improved plasma proteins, albumin, creatinine, and BUN levels. The oxidative stress was reduced in the kidney with the treatment of Triphala churna. Histopathological studies revealed that Triphala churna reduced kidney damage. Immunohistochemistry, ELISA, and western blotting study revealed that treatment with Triphala decreased the expression of TGF-β in kidney tissues.
CONCLUSION: From the results, it can be concluded that Triphala churna has a significant nephroprotective effect because of its capability of inhibiting oxidative stress and TGF-β in diabetes.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Diabetic complications; Diabetic nephropathy; Emblica officinalis; Terminalia belerica; Terminalia chebula; Triphala churna

Mesh:

Substances:

Year:  2020        PMID: 32674108     DOI: 10.1159/000508238

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  4 in total

1.  Combination therapy with artemether and enalapril improves type 1 diabetic nephropathy through enhancing antioxidant defense.

Authors:  Yijun Chen; Wenci Weng; Haiyang Zhang; Guangli Rong; Xuewen Yu; Qing Wei; Mumin Shao; Yuchun Cai; Pengxun Han; Huili Sun
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  Safety of the Oral Triphala Recipe from Acute and Chronic Toxicity Tests in Sprague-Dawley Rats.

Authors:  Warangkana Arpornchayanon; Subhawat Subhawa; Kanjana Jaijoy; Nirush Lertprasertsuk; Noppamas Soonthornchareonnon; Seewaboon Sireeratawong
Journal:  Toxics       Date:  2022-08-30

3.  Diphenyl Diselenide Alleviates Tert-Butyl Hydrogen Peroxide-Induced Oxidative Stress and Lipopolysaccharide-Induced Inflammation in Rat Glomerular Mesangial Cells.

Authors:  Xing Wang; Yi Huan; Shuainan Liu; Caina Li; Hui Cao; Lei Lei; Quan Liu; Wenming Ji; Sujuan Sun; Kaixun Huang; Jun Zhou; Zhufang Shen
Journal:  Int J Mol Sci       Date:  2022-09-23       Impact factor: 6.208

4.  Triphala Churna-A Traditional Formulation in Ayurveda Mitigates Diabetic Neuropathy in Rats.

Authors:  Sachin V Suryavanshi; Kalyani Barve; Veeranjaneyulu Addepalli; Sachin V Utpat; Yogesh A Kulkarni
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.